Strong tensions.SanderStock / iStock / Getty Images Plus / via Getty Images
ENtre on July 31 and August 7, 2025, the National Agency for Drug Safety and Health Products (ANSM) reported new disruptions or updated the availability data of severalspecialties marketed in France [1]distributed on the double canal city/hospital.
Lot reminder – Natispray 0.15 mg: Reminder of the Lot 24005T
Natispray 0.15 mg solution for oral spray (trinitrine)
Availability statement according to the ANSM
- Lot 24005T batch bottles are recalled due to a possible defect of quality: they may have leaks or even be empty.
- Patients with them a patch of the 24005T lot must bring it back to pharmacy to be replaced.
- Pharmacies having issued this product must contact the patients concerned in order to proceed to an exchange with a bottle of another lot.
Oncovin: again under tension in town
ONCOVIN 1 mg solution injectable (vincristine sulfate)
Availability statement according to the ANSM
- Situation in town: tension after a discount in 2023 (cf. Our article of December 21, 2023)
- Situation in the hospital: not impacted
- Date of discount scheduled: early November 2025
Quetiapine Viatris 300 mg and 400 mg Lp: Delay of production
Quetiapine Viatris LP 300 mg and 400 mg LP (Quetiapine Fumarate) tablet
Availability statement according to the ANSM
- Delay in the production of Quetiapine Viatris LP 300 mg and 400 mg LP tablet, accentuating the tendency tensions in Quétiapine currently encountered in France (cf. Our articles from July 17, 2025 and June 12, 2025).
- The Quetiapine Viatris LP 50 mg LP tablet is not concerned by this delay.
- Suspension of treatment initiationsexcept for patients with a depressed episode characterized as part of a bipolar disorder. The ANSM has communicated a list of therapeutic alternatives for prescribers.
- Possibility of unit dispensation (DAU) For all Quetiapine -based drugs, in accordance with the decree of February 12, 2025 modified including for 300 and 400 mg dosages. This allows pharmacists, in accordance with medical prescription and within the limits of a month of treatment, to adapt the quantities issued to the real needs of patients, in particular in the event of initiation or titration or when the boxes contain a large number of tablets (imported drugs).
- The ANSM communicated the Quétiapine LP equivalence table below.
- The DAU remains compulsory for the dispensation of medicines based on prolonged liberation quetiapine (LP) 50 mg, in accordance with the decree of February 12, 2025.
- In the event of unavailability of prolonged release drugs (LP), the Replacement with masterful preparations From Quétiapine to immediate liberation (Li) Without new medical prescription is possible.
- Replacement recommendation (ANSM, March 10, 2025).
- Information on masterful preparations :
Truvada and generics: in tension
Specialties of Emtricitabine/Tenofovir Disoproxil 200 mg/245 mg film -coated tablet of Gilead laboratories (Truvada), Viatris, Agreement, Arrow, Biogaran, EG Lab, Krka, Sandoz, Teva, Zentiva, Zydus (all specialties available on the market)
Availability statement according to the ANSM
Discount
The ANSM confirmed the following discount: